TNF Pharmaceuticals Return On Tangible Equity 2012-2024 | TNFA

TNF Pharmaceuticals return on tangible equity from 2012 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

TNF Pharmaceuticals Return On Tangible Equity 2012-2024 | TNFA

TNF Pharmaceuticals return on tangible equity from 2012 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$86.6B
Takeda Pharmaceutical (TAK)$46.8B
Merck (MKGAF)$24.9B
Summit Therapeutics (SMMT)$23.1B
Astellas Pharma (ALPMY)$21.7B
Sandoz Group AG (SDZNY)$17.9B
United Therapeutics (UTHR)$15.1B
Shionogi (SGIOY)$13.2B
Neurocrine Biosciences (NBIX)$12.3B
Catalent (CTLT)$10.8B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.7B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.3B
Crinetics Pharmaceuticals (CRNX)$4.3B
Corcept Therapeutics (CORT)$4B
Dyne Therapeutics (DYN)$3.4B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
PTC Therapeutics (PTCT)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Centessa Pharmaceuticals (CNTA)$1.9B
Recursion Pharmaceuticals (RXRX)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.6B
Ardelyx (ARDX)$1.5B
NewAmsterdam Pharma (NAMS)$1.4B